This is a working overview of Synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-16. Anything still debated is marked as such rather than presented as settled.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
Jesus himself identifies John as "Elijah who is to come", which is a direct reference to the Book of Malachi (Malachi 4:5), that has been confirmed by the angel who announced John's birth to his father, Zechariah. According to the Gospel of Luke, John and Jesus were relatives. Saint George was a Christian who is venerated as a saint in Christianity, and he was a soldier of Cappadocian Greek origin and member of the Praetorian Guard for Roman emperor Diocletian, who was sentenced to death for refusing to recant his Christian faith. He became one of the most venerated saints and megalomartyrs in Christendom, and he has been especially venerated as a military saint since the Crusades. In hagiography, as one of the Fourteen Holy Helpers and one of the most prominent military saints, he is immortalized in the legend of Saint George and the Dragon. His memorial, Saint George's Day, is traditionally celebrated on 23 April. England, Ethiopia, Georgia, Catalonia and Aragon in Spain, Moscow in Russia, and several other states, regions, cities, universities, professions and organizations claim George as their patron. The bones of Saint George are buried in the Church of Saint George, Lod, Israel.
Jung was introduced to Freud's work by Bleuler whilst working at Burghölzli Hospital. Bleuler asked him to write a review of The Interpretation of Dreams (1899), which he read in 1900. In the early 1900s, psychology as a science was still in its early stages, but Jung became a qualified practitioner of Freud's new "psycho-analysis". Freud needed collaborators and pupils to validate and spread his ideas. Burghölzli was a renowned psychiatric clinic in Zurich, and Jung's research had already gained him international recognition. Jung sent Freud a copy of his Studies in Word Association in 1906. The same year, he published Diagnostic Association Studies, a copy of which he later sent to Freud, who had already purchased a copy. Preceded by a lively correspondence, Jung met Freud for the first time in Vienna on 3 March 1907.Jung recalled the discussion between himself and Freud as interminable and unceasing for 13 hours. Six months later, the then 50-year-old Freud sent a collection of his latest published essays to Jung in Zurich. This began an intense correspondence and collaboration that lasted six years. In 1908, Jung became an editor of the newly founded Yearbook for Psychoanalytical and Psychopathological Research. In the late summer of 1909, Jung sailed with Freud and Hungarian psychoanalyst Sándor Ferenczi to the United States. From 7–11 September, they took part in the twentieth-anniversary celebration of the founding of Clark University in Worcester, Massachusetts, the Vicennial Conference on Psychology and Pedagogy.
== Bibliography == Sammond, Nicholas (2005). Steel Chair to the Head: The Pleasure and Pain of Professional Wrestling. Duke University Press. ISBN 978-0-8223-3438-5. Foley, Mick (2000). Have A Nice Day: A Tale of Blood and Sweat Socks. Harper Collins. ISBN 978-0-06-103101-4. PSI Staff (2007). Pro Wrestling Illustrated Presents: 2007 Wrestling Almanac & Book of Facts. Kappa Publishing. Austin, Steve; Ross, Jim; Brent, Dennis (2003). The Stone Cold Truth. Pocket Books. ISBN 978-0-7434-7720-8.
Similarly to other classic psychedelics, DET acts as a non-selective serotonin receptor agonist, including of the serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors. The drug has been shown to activate Gq-mediated signaling at the serotonin 5-HT2A receptor with Emax higher than 70% and to produce the head-twitch response in rodents which is a behavioral proxy of psychedelic-like effects. It is also a serotonin receptor agonist in the rat uterus and stomach strip, with slightly greater potency than dimethyltryptamine (DMT). DET is a very weak reversible monoamine oxidase inhibitor (MAOI), with IC50Tooltip half-maximal inhibitory concentration values of 59 μM for serotonin and 5,000 μM for tryptamine as substrates. Injections of 30 mg/kg to rats resulted in 67% reduction of brain MAO-A activity 15 minutes after administration. The substance may also act as a serotonin reuptake inhibitor, with low affinity but moderate potency. It shows no activity as a norepinephrine or dopamine reuptake inhibitor.
(b) Nasal dorsum and lateral nasal wall defect The size of the nasal defect (wound) occurred, in either the dorsum or the lateral wall, or both, determines the reconstructive skin-flap technique applicable to the corresponding aesthetic nasal subunits.
Sources: en.wikipedia.org
In March 2002, Yorkshire merged with Tricon Global Restaurants to form Yum! Brands. A few weeks later, Malaysian company KUB took over the franchises in Southeast Asia, aiming to restore its prestige in Malaysia alone and increasing its market share. Subsequently, in January 2003, Yum! announced that A&W and Long John Silver's would move their operational base from Lexington to Louisville, as operating the chains from Lexington was considered "impractical and cost-inefficient", preferring to operate all of its chains from Louisville. Under Yum's management, A&W added franchises with a nostalgic look and modern technology. They have a carhop design with drive-thrus, and some have picnic tables. The chain didn't seek to compete against McDonald's, instead preferring to carve up its own niche. 2004 saw the return of the Papa Burger brand at a restaurant in Dayton - the Burger Family brand originally retired in the United States in the 1980s, being replaced by the Deluxe Burgers - and was the only name of the old line that was reinstated, with the other burgers having new names. In September 2001 the Singapore branch was taken over by KUB, who also oversaw the restaurants in Malaysia. At the time of takeover, it had twelve restaurants, but by November 2002, the number had dwindled to eight. Its restaurants had already been downgraded: the Ang Mo Kio restaurant shut down, the Tampines restaurant refused to repair its air conditioning systems, and cable TV was switched off in all outlets. Food sales had decreased by about 5-12%.
Historically, the birth rate of teenagers peaked in the late 1950s and early 1960s. However, at that time, most teenage parents were married. In the early twenty-first century, nine in ten births to the age group 15-19 are to unmarried mothers. Social norms have changed; it is now not unusual for teenagers to delay or avoid sexual intercourse altogether. Younger teenagers are more likely to practice abstinence than their older counterparts. A report published by the Center for Disease Control and Prevention (CDC) in early 2018 found the number of high school students who have had sex fell from 47% in 2005 down to 41% in 2015, with the most dramatic drop taking place between 2013 and 2015. On top of that, among never-married teens who have had sex, overwhelming majorities reported they used contraception the first time they did it. There are a few reasons for this. First, Millennials and Generation Z are more focused on the consequences of sex than their predecessors were. Second, there has been growing concern over unwanted sexual advances, especially in the wake of the Me-too movement. Writing for The Spectator, Douglas Murray dubbed this the "sexual counter-revolution." Third, as a consequence of the precarious contemporary economy, young adults today are more likely to be living with their parents rather than on their own, with a romantic partner, or a spouse. A 2016 analysis by the CDC discovered that teenage birthrates nosedived between 1991, when they reached a crisis point, and 2014, when they dropped by 60%, a record low.
== Professional organizations for clinical data management == International Network of Clinical Data Management Associations (INCDMA) aims at the promotion of collaboration among clinical data management groups around the world. It is an international forum for discussion of and feedback on current topics of relevance to the discipline of CDM. It is composed of members the boards of the SCDM, ACDM, DMB (France), PSDM (The Netherlands) who participate in the INCDMA proceedings and funding. It also regroups DM leaders and subject matter experts from Europe, North America, Israel, Japan, China and Australia. The Association for Clinical Data Management (ACDM) is a global organization founded in 1987 and is Empowering Excellence in Clinical Data Management. The ACDM represents a vibrant community of dedicated clinical research professionals who are passionate about enhancing the drug development process through fostering an environment that encourages continuous learning and the practical application of modern Clinical Data Management practices. With over 35 years of service to the data management community, the ACDM's unwavering commitment is to provide clear and effective platforms for its members to network, share experiences, and stay abreast of the latest regulations and standards in Clinical Data Management. Along with supporting members on their professional development journeys, offering opportunities to gain the skills and insights needed to excel in their careers and shape the future of data management.
=== Spectroscopy === In quantum mechanics, the energy levels of electrons in atoms depend on the reduced mass of the system of electron and nucleus. For a hydrogen atom, the role of reduced mass is most simply seen in the Bohr model of the atom, where the reduced mass appears in a simple calculation of the Rydberg constant and Rydberg equation, but the reduced mass also appears in the Schrödinger equation, and the Dirac equation for calculating atomic energy levels. The reduced mass of the system in these equations is close to the mass of a single electron, but differs from it by a small amount about equal to the ratio of mass of the electron to the nucleus. For 1H, this amount is about 1837/1836, or 1.000545, and for 2H it is even smaller: 3671/3670, or 1.000272. The energies of electronic spectra lines for 2H and 1H therefore differ by the ratio of these two numbers, which is also very close to 1.000272. The wavelengths of all deuterium spectroscopic lines are shorter than the corresponding lines of light hydrogen, by 0.0272%. In astronomical observation, this corresponds to a blue Doppler shift of 0.0272% of the speed of light, or 81.6 km/s. The differences are much more pronounced in vibrational spectroscopy such as infrared spectroscopy and Raman spectroscopy, and in rotational spectra such as microwave spectroscopy because the reduced mass of the deuterium is markedly higher than that of protium. In nuclear magnetic resonance spectroscopy, deuterium has a very different NMR frequency (e.g. 61 MHz when protium is at 400 MHz) and is much less sensitive.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.